Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

IntroductionChimeric antigen receptor (CAR) T-cell therapy (CAR T therapy) is a treatment option for patients with relapsed or refractory multiple myeloma that has led to unprecedented treatment outcomes. Among CAR T therapies available, ciltacabtagene autoleucel (cilta-cel) is a good candidate for...

Descripció completa

Dades bibliogràfiques

Autors principals:	Doris K. Hansen, Binod Dhakal, Mehdi Hamadani, David Dingli, Tania Jain, Carol Ann Huff, Murali Janakiram, Yi-Hsuan Liu, Kevin C. De Braganca, Nicole Lodowski, Jennifer Sander, Peter Okorozo, Lindsay McFarland, Matthew Perciavalle, Stephen Huo, Zaina P. Qureshi, Krina K. Patel
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-06-01
Col·lecció:	Frontiers in Immunology
Matèries:	ciltacabtagene autoleucel cilta-cel outpatient car t therapy CAR T-cell relapsed or refractory multiple myeloma
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1405452/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!